Eli Lilly’s Obesity Drug Retatrutide Leads To 24.2% Weight Loss In Phase 2 Trial
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Eli Lilly and Co. (LLY) said results from phase 2 clinical trial showed that people treated with the highest dose of retatrutide achieved a mean weight reduction of 24.2% at the end of the 48-week. This translates to an average absolute weight reduction of about 58 po
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1803777103-b9626d35c9fd4424ae7ecc3b6d58a558.jpg "Accountant Career Path and Qualifications")
:max_bytes(150000):strip_icc():format(jpeg)/AFFLUENT.MILLENNIAL.HERO.GettyImages-868506558_2600-84706e45802340b1865d4b49c285a662.jpg "The Affluent Millennial Investing Survey")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2151279555-f38549a64433496982ff93944b309afb.jpg "5 Transamerica Mutual Funds to Consider")
